Colon cancer is the second leading cause of cancer deaths in the United States and the third most common type of cancer which is diagnosed in men and women. Troubling health care providers is the fact that colorectal cancer is a very preventable disease. In 2005 nearly 145,000 cases were diagnosed and over 50,000 people died of colon cancer. Screening and prevention are top priorities for primary care physicians and health policy makers. Controversial data has emerged about the role of COX-2 inhibitor drugs, like Celebrex, Vioxx and Bextra, in preventing colon cancer.
These anti-inflammatory drugs prescribed for painful osteoarthritis may actually protect against developing colon cancer. Unfortunately, these drugs are also associated with increased risk of cardiovascular events, with Vioxx and Bextra being removed from the market. A research study presented at the American Association for Cancer Research earlier in 2006 demonstrated that patients at high risk of developing colon cancer who took Celebrex (celecoxib) had a 45% lower incidence of benign tumors found during colonoscopy and a 65% lowered risk of developing invasive cancer. The study was terminated early due to the 100-200% increased risk of developing cardiovascular problems.
While these drugs will probably not be recommended for prevention of colon cancer due to the adverse effects, the information is quite valuable. Certain foods and medicinal plants, like turmeric, have the same COX-2 inhibiting effects, without causing cardiovascular problems. Large scale studies are needed to determine the effect on colon cancer reduction. In the meantime, eating a high fiber diet rich in colorful fruits and vegetables, and regular medical screening is the best way to reduce the risk of cancer of the colon.
Posted by Dr. Jennifer Stagg on July 30, 2006 06:42 AM
